IRCT20200822048478N2 IRCT 2020-10-04 Kashan University of Medical Sciences Continuous infusion of Esmolol in patients undergoing CABG surgery Comparison study of continuous infusion and bolus of Esmolol on hemodynamic response to laryngoscopy and endotracheal intubation in coronary artery bypass graft patients 2015-07-23 anticipated 66 Complete https://irct.ir/trial/51295 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We are going to randomize based on Permuted block randomization method. In this way, all 6 groups of 3 groups (20 blocks) are determined and using the random number table, the number of blocks is selected and a sequence of groups A, B and c is determined and each patient is based on the entry number. The plot is placed in one of the groups, Blinding description: After consciously agreeing to participate in the study, patients are randomly assigned to one of three study groups. researchers, evaluators of the outcome, and data Analyzer don't know about which patient is in which One of the treatment groups. 3 Coronary artery disease. Intervention 1: Infusion group: 0.5 mg/kg Esmolol is injected within 4 minutes and then the infusion is started at 200 μg/kg/min and continues until endotracheal intubation. 0.9% Nacl is administered 2 minutes before endotracheal intubation. Esmolol is manufactured by Claris company, India. Intervention 2: Bolus group: 1.5mg/kg Esmolol is administered as a venous bolus 2 minutes before intubation and 0.9 Nacl% is administered 10 minutes before endotracheal intubation until it. Esmolol is manufactured by Claris company, India. Intervention 3: Control group: 0.9% Nacl infusion and bolus of normal saline are given instead of Esmolol. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I have not decided yet